Uncategorized
Replimune melanoma drug wins support of FDA panel
The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.
The positive vote came despite persistent concerns from FDA scientists and positions the company to bounce back from two earlier rejections.